Neoadjuvant therapy

Phase 3Small molecule

SSun Yat-sen University

Neoadjuvant therapy is one of 190 small molecule programs targeting Adverse Effect. It is currently in Phase 3.

Indications

Total Trials

Active Trials

189

Competitors

Pipeline

Status by Indication[3][1]

Indication

Adverse EffectActive, not recruiting

Gastroesophageal Junction AdenocarcinomaNot yet recruiting

Non-Small Cell Lung CancerRecruiting

Cervical CancerRecruiting

NSCLCRecruiting

Narrow MarginRecruiting

Pathological Complete ResponseNot yet recruiting

Adverse EffectPreclinical

Active, not recruiting

Gastroesophageal Junction AdenocarcinomaPhase 2

Not yet recruiting

Non-Small Cell Lung CancerPhase 3

Recruiting

Cervical CancerPhase 3

Recruiting

NSCLCPhase 2

Recruiting

Narrow MarginPhase 3

Recruiting

Pathological Complete ResponsePhase 2

Not yet recruiting

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Lazcluze

Johnson & Johnson

Phase 3

8 2

Lynparza

AstraZeneca

Phase 3

6 3

Rozlytrek

Roche

Phase 3

4 4

Neoadjuvant therapy

SSun Yat-sen University

Phase 3

2 5

Remeron

OOrganon and Co

Preclinical

1 6

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

1 7

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—8

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—9

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Not yet recruiting

Pathological Complete Response

NCT06851169

Q4 2027

Phase 2Not yet recruiting

Gastroesophageal Junction Adenocarcinoma

NCT06766578

Q1 2028

Phase 2Not yet recruiting

Gastroesophageal Junction Adenocarcinoma

NCT06829797

Q3 2028

Phase 2Recruiting

NSCLC

NCT07089199

Clinical

Trials by Indication[1]

Breast Cancer3 trials

The Detection of Cell-in-cell Structure (CICs) in Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy

Unknown status·—··NCT05642104·175 enrolled

Paclitaxel and Radiation Therapy in Treating Patients Undergoing Surgery for Stage II or Stage III Breast Cancer

Completed·VVanderbilt-Ingram Cancer Center·N/A·NCT00647218·38 enrolled

Comparative Study of Neoadjuvant Chemotherapy With and Without Zometa for Management of Locally Advanced Breast Cancers

Completed·HHospices Civils de Lyon·Phase 2·NCT01367288·53 enrolled

Gastroesophageal Junction Adenocarcinoma2 trials

A Multicenter Randomized Controlled Phase II Trial of Iparomlimab and Tuvonralimab (QL1706) Combined with SOX Chemotherapy Versus Chemotherapy Alone in the Treatment of Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Not yet recruiting·SShandong Provincial Hospital·Phase 2·NCT06829797·96 enrolled

Clinical Study of Low-dose Interval Radiotherapy Combined With Tirelizumab and SOX Chemotherapy Neoadjuvant Therapy for Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

Not yet recruiting·SShandong Provincial Hospital·Phase 2·NCT06766578·32 enrolled

Non-Small Cell Lung Cancer2 trials

Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer

Recruiting·SSun Yat-sen University·Phase 3·NCT06734702·497 enrolled

A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade in Patients With Locally Advanced Non-Small Cell Lung Cancer

Recruiting·SSun Yat-sen University·Phase 2·NCT07103395·56 enrolled

NSCLC2 trials

Tislelizumab Combined With Anlotinib and Nab-paclitaxel in III Resectable Non-small Cell Lung Cancer : A Prospective, Single-Arm, Phase II Study

Recruiting·QQilu Hospital of Shandong University·Phase 2·NCT07089199·34 enrolled

Multimodal Ablation Combined With Perioperative Tislelizumab and Chemotherapy for Resectable II-IIIB NSCLC

Not yet recruiting·CCancer Institute and Hospital, Chinese Academy of Medical Sciences·Phase 2·NCT07729670·42 enrolled

Neoadjuvant Treatment1 trial

Long-term Survival Outcomes According to the Pathologic Response After Neoadjuvant Treatment in PDAC and the Fate of the Patients with Good CAP Grade

Completed·SSeoul National University Hospital··NCT06630481·462 enrolled

8 more indications

Pathological Complete Response1 trial

This is a Two-cohort, Exploratory Clinical Study Assessing the Activity of Benmelstobart Alone or Combined with Anlotinib Administered Prior to Surgery in Terms of Pathological Complete Response

Not yet recruiting·TTang-Du Hospital·Phase 2·NCT06851169·58 enrolled

Cervical Cancer1 trial

Induction Chemotherapy Combined With Immunotherapy Followed by Concurrent Chemoradiation in Advanced Cervical Cancer

Recruiting·SSichuan Cancer Hospital and Research Institute·Phase 3·NCT05173272·286 enrolled

Rectal Cancer1 trial

Factors Predicting Recurrence in Rectal Cancer After Surgery

Completed·Aammar houssem··NCT03899870·188 enrolled

Narrow Margin1 trial

Wide Margin vs. Narrow Margin in Postneoadjuvant Lumpectomy

Recruiting·MMansoura University·Phase 3·NCT03417622·370 enrolled

Neoadjuvant1 trial

Neoadjuvant Database

Unknown status·CCentre Georges Francois Leclerc··NCT04031612·2,000 enrolled

Adverse Effect1 trial

Effect of Vitamin D Supplementation on the Efficacy and Adverse Effects of Neoadjuvant Therapy in Patients with Breast Cancer

Recruiting·JJiuda Zhao·N/A·NCT06642428·140 enrolled

Prostate Cancer1 trial

Luteinizing Hormone-Releasing Hormone Agonist Therapy and Iodine I 125 Implant in Treating Patients With Previously Untreated Prostate Cancer

Completed·TTranslational Research Center for Medical Innovation, Kobe, Hyogo, Japan·Phase 3·NCT00664456·421 enrolled

Bladder Cancer1 trial

Luminal Bladder Cancer Effective Response to Neoadjuvant Chemotherapy (LUMBER-NAC)

Recruiting·RRutgers, The State University of New Jersey·Phase 2·NCT07762586·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 18 trial records for Neoadjuvant therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Neoadjuvant therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Neoadjuvant therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sun Yat-sen University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSun Yat-sen University

Neoadjuvant therapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2027

Q1 2028

Q3 2028

Trials by Indication[1]

Breast Cancer3 trials

Gastroesophageal Junction Adenocarcinoma2 trials

Non-Small Cell Lung Cancer2 trials

NSCLC2 trials

Neoadjuvant Treatment1 trial

Pathological Complete Response1 trial

Cervical Cancer1 trial

Rectal Cancer1 trial

Narrow Margin1 trial

Neoadjuvant1 trial

Adverse Effect1 trial

Prostate Cancer1 trial

Bladder Cancer1 trial

References

Drug Info

Quick Facts

Related News